2020

Caspase-9 inhibiting eyedrops rescue physiological and functional retinal vein occlusion damage shown with Phoenix MICRON®, OCT, and focal ERG

In a recent well written, compelling article published in Nature Communications, “Endothelial activation of caspase-9 promotes neurovascular injury in retinal vein occlusion,” Avrutsky et al show that caspase-9 inhibition is a promising treatment for retinal vein occlusion. Retinal vein occlusion models hypoxic-ischemic neurovascular damage and is the second leading cause of blindness in working-age adults.

2020

Targeting VEGF164 in Müller cells may be useful to treat retinopathy of prematurity

In Nature’s Scientific Reports, Becker et al use the Phoenix MICRON® IV, OCT, and focal ERG to assess the therapeutic value of knocking down a splice variant of VEGF in Müller cells in a model of Retinopathy of Prematurity (ROP). ROP is characterized by delayed vascularization of the retina after disrupted oxygen levels, followed by

1 2